Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cirtuvivint and Olaparib in Platinum Resistant Ovarian Cancer
NCT06856499Phase 1Recruiting
- Sponsor
- University of Colorado Denver
- Start
- Dec 2025
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cirtuvivint in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by University of Colorado Denver. Primary endpoints: Safety and Tolerability at 6 months and Recommended Phase 2 Dose at 6 months. Started Dec 2025; status: recruiting.
02
Drugs
cirtuvivint
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT06856499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06856499.